| Story Views | |
| Now: | |
| Last Hour: | |
| Last 24 Hours: | |
| Total: | |
Windtree Therapeutics blows higher on positive phase 2b trial news
Windtree Therapeutics Inc (NASDAQ: WINT) shares added over 24% in New York as it posted positive clinical trial timeline news.
The firm, which is developing therapies for respiratory diseases, said an independent data safety monitoring board had completed its second and final interim safety review on the AEROSURF phase 2b trial.
The board has recommended continuing the trial without modifying it.
Windtree also revealed today it plan to announce top-line results from the trial in mid-year 2017.
“We are very encouraged by the AEROSURF safety and tolerability profile to date and by the progress we have made with patient enrollment in this trial,” said Steve Simonson, Senior Vice President and Chief Development Officer at Windtree.
“We believe that AEROSURF, if successful, has the potential to transform the treatment of RDS in premature infants.
“We look forward to completing this clinical trial and sharing top-line results in mid-2017.”
The AEROSURF phase 2b clinical trial is a multicenter, randomized, controlled study.
It is being conducted in around 50 clinical sites in North America, Europe and Latin America.
Shares added 24.19% to $1.54 each.
Story by ProactiveInvestors
